Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Julie Braish, MBBCh, a third-year fellow at MD Anderson, presented data on azacitidine and venetoclax in HR-MDS and CMML.
Presented preclinical model data show significant efficacy against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Naval Daver, MD, discusses the latest advancements in the treatment of myelodysplastic syndromes
Advertisement
At The HemOnc Pulse Live!, experts debate key controversies in MDS care, from frontline therapy to emerging treatments.
Mice treated with CLK3 TCR9-T cells had a significantly lower tumor burden than those who received control treatments.
Anderw Brunner, MD addresses current gaps in MDS research and clinical practice and more.
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
The investigational small molecule enzomenib has received FDA Orphan Drug and Fast Track designations in AML.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
The approval was based on the phase 3 IMerge study, which showed improved rates of transfusion independence with imetelstat.
MRD testing before HSCT may offer insight into survival outcomes for patients with MDS/MPN.
The phase 2 prospective trial with these results also evaluated overall survival, nonrelapse mortality, and relapse rates.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.